Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended Anti-IL-23 antibody. The treatment is being tested for curing inflammatory bowel disease and rheumatic diseases. ​During the trial, SPY003 showed a half-life of approximately 85 days, supporting maintenance dosing of three or six months. Management noted that the trial w ...